BCR-ABL Mutations in Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors and Impact on Survival

Autor(es):Mostrar menos -

Barbosa Pagnano, Katia Borgia ^[1] ; Bendit, Israel ^[2] ; Boquimpani, Carla ^[3] ; De Souza, Carmino Antonio ^[1] ; Miranda, Eliana C. M. ^[1] ; Zalcberg, Ilana ^[4] ; Larripa, Irene ^[5] ; Nardinelli, Luciana ^[2] ; Silveira, Rosana Antunes ^[1] ; Fogliatto, Laura ^[6] ; Spector, Nelson ^[7] ; Funke, Vaneuza ^[8] ; Pasquini, Ricardo ^[8] ; Hungria, Vania ^[9] ; Chiattone, Carlos Sergio ^[9] ; Clementino, Nelma ^[10] ; Conchon, Monika ^[11] ; Beatriz Moiraghi, Elena ^[12] ; Lopez, Jose Luis ^[13] ; Pavlovsky, Carolina ^[14] ; Pavlovsky, Miguel A. ^[14] ; Cervera, Eduardo E. ^[15] ; Antonio Meillon, Luis ^[16] ; Simoes, Belinda ^[17] ; Hamerschlak, Nelson ^[18] ; Magarinos Bozzano, Alicia Helena ^[19] ; Mayta, Ernesto ^[20] ; Cortes, Jorge ^[21] ; Bengio, Raquel M. ^[5] ; LALNET, Latin Amer Leukemia Net

Afiliação do(s) autor(es):Mostrar menos -

^[1] Univ Estadual Campinas, UNICAMP, Hemoctr, BR-13083878 Campinas, SP - Brazil

^[2] Univ Sao Paulo, Lab Biol Tumoral, Sao Paulo, SP - Brazil

^[3] Hemorio, Rio De Janeiro, RJ - Brazil

^[4] Inst Nacl Canc, Rio De Janeiro, RJ - Brazil

^[5] Acad Nacl Med Buenos Aires, Inst Invest Hematol, Buenos Aires, DF - Argentina

^[6] Hosp Clin Porto Alegre, Porto Alegre, RS - Brazil

^[7] Univ Fed Rio de Janeiro, Rio De Janeiro, RJ - Brazil

^[8] Univ Fed Parana, BR-80060000 Curitiba, Parana - Brazil

^[9] Santa Casa Sao Paulo, Sao Paulo, SP - Brazil

^[10] Univ Fed Minas Gerais, Belo Horizonte, MG - Brazil

^[11] Hosp Santa Marcelina, Sao Paulo, SP - Brazil

^[12] Hosp Ramos Mejia, Buenos Aires, DF - Argentina

^[13] Banco Municipal Sangre DC, Caracas - Venezuela

^[14] FUNDALEU, Buenos Aires, DF - Argentina

^[15] INCAN, Mexico City, DF - Mexico

^[16] Ctr Med Nacl Siglo XXI, Mexico City, DF - Mexico

^[17] Univ Sao Paulo, BR-14049 Ribeirao Preto, SP - Brazil

^[18] Hosp Israelita Albert Einstein, Sao Paulo, SP - Brazil

^[19] Hosp Maciel, Montevideo - Uruguay

^[20] Inst Oncol Nacl, Panama City - Panama

^[21] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 - USA

• Tipo de documento: Artigo Científico
• Fonte: CANCER INVESTIGATION; v. 33, n. 9, p. 451-458, 2015.
• Citações Web of Science: 8

Resumo

This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n=31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p=0.07 and 47% vs. 72%, p=0.03, respectively) and in those with the T315I mutation (p=0.003 and p=0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p=0.01; PFS: 48% vs. 30% p=0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients. (AU)

• Processo FAPESP: 05/59708-6 - Avaliacao da resistencia ao mesilato de imatinibe em pacientes com leucemia mieloide cronica pela presquisa de mutacoes do gene bcr/abl e analise do perfil de expressao genica de pacientes pre e apos...
• Beneficiário: Rosana Antunes da Silveira
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 03/09054-4 - Avaliação de mutações de ponto do gene BCR/ABL em pacientes com leucemia mielóide crônica resistentes ao Glivec
• Beneficiário: Katia Borgia Barbosa Pagnano
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 03/12605-2 - Avaliação de mutações de ponto no gene BCR/ABL em pacientes com leucemia mielóide crônica resistentes ao mesilato de Imatinib (Glivec)
• Beneficiário: Edson Ichihara
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica